Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Metformin Modulates Gut Microbiome, Improves Glycemic Control

By R&D Editors | June 18, 2014

MicroBiome Therapeutics LLC reported that a recently published scientific study shows that the diabetes drug, metformin, alters the bacterial populations in the gut in favor of a bacterial species that exerts specific cellular and immunological effects, resulting in improved glycemic control. This is the first study to demonstrate a link between metformin and changes in the gut microbiota and it provides insights into the possible mechanism of action of NM504 and NM505, MBT’s lead microbiome modulators in clinical development for diabetes and prediabetes.  Metformin is a first-line treatment for type 2 diabetes and the seventh most prescribed drug in the United States.
 
The new study, recently published in the journal Gut, showed that metformin treatment significantly improved the glycemic profile of mice that became obese after receiving a high fat diet. Researchers also showed that metformin induced a change in the composition of the GI microbiota in these mice, increasing the population of a bacterial strain known as Akkermansia. Akkermansia acts to increase the number of goblet cells in the gut. These produce protective mucous that helps keep the lining of the intestinal tract healthy and functional. In these mice, Akkermansia also affected certain immune responses, stimulating the production of regulatory T-cells that act to reduce the prevalence of fat cell-generated pro-inflammatory cytokines, which are associated with obesity and glucose intolerance.
 
To confirm the role of Akkermansia in producing these beneficial effects, the researchers administered Akkermansia to the obese mice in place of metformin. Akkermansia alone produced a similar improvement in glycemic control. The authors concluded that increases in Akkermansia may constitute a novel mechanism for the antidiabetic activity of metformin and that pharmacological modulation of the gut microbiome could offer new ways to treat type 2 diabetes.
 
“This elegant study, the first to demonstrate a link between the antidiabetic efficacy of metformin and changes in the gut microbiome, may offer insights into why the pilot study testing our microbiome modulator, NM504, in combination with metformin produced an unexpectedly large drop in blood glucose levels beyond what had been achieved with metformin alone,” noted Steve Orndorff, CEO of MicroBiome Therapeutics. “We look forward to sharing the results from our NM504/metformin clinical study, which are expected shortly.”
 
MBT’s microbiome modulator, NM504, is in a confirmatory proof of concept clinical study testing its ability to improve blood glucose levels and decrease gastrointestinal side effects in type 2 diabetes patients taking metformin. In a published case report, co-administration of NM504 eliminated the dose-limiting diarrhea caused by metformin in a metformin-intolerant patient with newly-diagnosed diabetes and produced additional large decreases in his highly elevated blood glucose levels. Based on its work with NM504, MBT has developed a reformulated version of metformin called NM505, which combines metformin with proprietary microbiome modulators. The company is preparing to launch a clinical study testing the ability of NM505 to improve metformin tolerability and reduce the dose-limiting GI side effects commonly associated with metformin use.
 
MBT is also developing microbiome modulator NM504, which alters the GI microbiome to enhance insulin sensitivity and glycemic control in individuals with prediabetes and diabetes. The company previously reported top-line results from a double-blind, randomized, placebo-controlled trial showing that oral administration of NM504 alone significantly reduced postprandial serum glucose levels and increased insulin sensitivity in subjects with prediabetes and untreated type 2 diabetes. In this study, NM504 was well tolerated. More complete data from the NM504 study will be discussed in a podium presentation at the upcoming ICE/ENDO 2014 meeting in Chicago, Illinois.
 
MBT’s evidence-based microbiome modulators are designed to alter bacterial populations and their environment in the GI tract to treat and prevent serious health conditions. MBT’s microbiome modulators act on multiple factors, providing selective substrates that augment the growth of targeted desirable bacterial strains and discourage the growth of others that may be harmful. These shifts in the GI microbiome have the potential to have a major impact on factors affecting metabolism and weight. 
 
Date: June 17, 2014
Source: MicroBiome

Related Articles Read More >

Open-source Boltz-2 can speed binding-affinity predictions 1,000-fold
Thermo Fisher’s new Orbitrap Excedion Pro targets complex biotherapeutics for drug development
FDA’s new ‘Elsa’ AI set to expedite clinical protocol reviews
Waters touts six-fold robustness with new Xevo TQ Absolute XR
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE